The Aftermath of a 'Miracle Cure' for a Rare Cancer
By James Tabery,
Wired
| 09. 04. 2023
You really can't understand all the excitement surrounding personalized medicine without knowing a little bit about Gleevec. And once you know the full story of Gleevec, you really can’t help but see much of that excitement as wild and even dangerous exaggeration.
Personalized medicine (sometimes it’s also called “precision medicine”) works by tailoring health care to our genomes. Traditional, one-size-fits-all medicine, the criticism goes, treats us all as if we’re the same, but personalized medicine tracks the molecular-genetic differences between us to deliver the right treatment, to the right patient, at the right time. The approach has gotten its most purchase in the management of cancers and rare diseases, but champions foresee a future where it spreads out across all facets of health care, revolutionizing the treatment of everything from diabetes and cardiovascular disease to asthma and rheumatoid arthritis. A big part of the enthusiasm is economic in nature. Rather than sending patients off on costly and frustrating trial-and-error odysseys, advocates of precision medicine see its ability to find the right gene-treatment matches from the beginning of care...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...